Roche/Genentech win expanded Avastin use in colorectal cancer
This article was originally published in Scrip
Executive Summary
The US FDA gave its OK on 23 January for Genentech, a unit of Roche, to market a new metastatic colorectal cancer (mCRC) treatment strategy for Avastin (bevacizumab) – expanding the drug’s labeling to allow doctors to use the recombinant humanized monoclonal IgG1 antibody in combination with fluoropyrimidine-based irinotecan or oxaliplatin.